Patents by Inventor Sarvajit Chakravarty

Sarvajit Chakravarty has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-cancer nuclear hormone receptor-targeting compounds
    Patent number: 12208141
    Abstract: The disclosure relates to anti-cancer compounds derived from nuclear steroid receptor binders, to products containing the same, as well as to methods of their use and preparation.
    Type: Grant
    Filed: September 22, 2023
    Date of Patent: January 28, 2025
    Assignee: NUVATION BIO INC.
    Inventors: David Hung, Son Minh Pham, Sarvajit Chakravarty, Jiyun Chen, Jayakanth Kankanala, Jeremy D. Pettigrew, Anup Barde, Anjan Kumar Nayak
  • ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF
    Publication number: 20240352046
    Abstract: The present invention discloses compounds useful in treatment of conditions associated with dysfunction of ectonucleotide pyrophosphatase/phosphodiesterase-1 (ENPP1) enzyme. Specifically, the present invention discloses compound of formula (J) which exhibit inhibitory activity against ENPP1. Method of treating conditions associated with over-expression of ENPP1 gene with such compound is disclosed. Uses thereof, pharmaceutical composition, and kits are also disclosed.
    Type: Application
    Filed: June 13, 2024
    Publication date: October 24, 2024
    Inventors: Brahmam Pujala, Amantullah Ansari, Shreya Sapra, Pradeep S. Jadhavar, Dhananjay Pendharkar, Sreekanth A. Ramachandran, Uzma Saeed, Abhinandan Danodia, Farha Khan, Sagar Patni, Sanjeev Soni, Ashu Gupta, Sarvajit Chakravarty, Balaji Dashrath Sathe
  • Anti-cancer nuclear hormone receptor-targeting compounds
    Patent number: 11826430
    Abstract: The disclosure relates to anti-cancer compounds derived from nuclear steroid receptor binders, to products containing the same, as well as to methods of their use and preparation.
    Type: Grant
    Filed: May 13, 2020
    Date of Patent: November 28, 2023
    Assignee: NUVATION BIO INC.
    Inventors: David Hung, Son Minh Pham, Sarvajit Chakravarty, Jiyun Chen, Jayakanth Kankanala, Jeremy D. Pettigrew, Anup Barde, Anjan Kumar Nayak
  • HETEROCYCLIC COMPOUNDS AS BET INHIBITORS
    Publication number: 20230339964
    Abstract: Novel bromodomain and extraterminal domain (BET) inhibitors and to therapeutic methods of treating conditions and diseases using these novel BET inhibitors are provided.
    Type: Application
    Filed: January 9, 2023
    Publication date: October 26, 2023
    Inventors: Son Minh PHAM, Sarvajit Chakravarty, Jayakanth Kankanaka, Jiyun Chen, Chris P. Miller, Jeremy D. Pettigrew, Anjan Kumar Nayak, Anup Barde
  • Compounds and methods of use
    Patent number: 11702401
    Abstract: This disclosure provides compounds and compositions and methods of using those compounds and compositions to treat diseases and disorders associated with excessive transforming growth factor-beta (TGF?) activity. This disclosure also provides methods of using the compounds in combination with one or more cancer immunotherapies.
    Type: Grant
    Filed: May 22, 2021
    Date of Patent: July 18, 2023
    Assignee: Medivation Technologies LLC
    Inventors: Roopa Rai, Sarvajit Chakravarty, Brahmam Pujala, Bharat Uttam Shinde, Anjan Kumar Nayak, Anil Kumar Agarwal, Sreekanth A. Ramachandran, Son Minh Pham
  • ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS
    Publication number: 20230122310
    Abstract: The disclosure relates to anti-cancer compounds derived from nuclear steroid receptor binders, to products containing the same, as well as to methods of their use and preparation.
    Type: Application
    Filed: November 22, 2022
    Publication date: April 20, 2023
    Inventors: David Hung, Son Minh Pham, Sarvajit Chakravarty, Jiyun Chen, Jayakanth Kankanala, Anup Barde, Anjan Kumar Nayak
  • HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS
    Publication number: 20230062022
    Abstract: Heterocyclic compounds as CDK4 or CDK6 or other CDK inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.
    Type: Application
    Filed: October 1, 2021
    Publication date: March 2, 2023
    Inventors: Son Minh PHAM, Sarvajit Chakravarty, Jayakanth Kankanala, Brahmam Pujala, Amit Shete, Bhawana Bhatt, Anil Kumar Agarwal, Sanjeev Soni, Jiyun Chen
  • Heterocyclic compounds as BET inhibitors
    Patent number: 11584756
    Abstract: Novel bromodomain and extraterminal domain (BET) inhibitors and to therapeutic methods of treating conditions and diseases using these novel BET inhibitors are provided.
    Type: Grant
    Filed: July 1, 2020
    Date of Patent: February 21, 2023
    Assignee: NUVATION BIO INC.
    Inventors: Son Minh Pham, Sarvajit Chakravarty, Jayakanth Kankanala, Jiyun Chen, Chris P. Miller, Jeremy D. Pettigrew, Anjan Kumar Nayak, Anup Barde
  • Derivatives of piperlongumine and uses thereof
    Patent number: 11485725
    Abstract: The present invention relates to a group of 1-[(E)-3-(3,4,5-trimethoxyphenyl)prop-2-enoyl]-2,3-dihydropyridin-6-one (piperlongumine) derivatives, analogs and pharmaceutically acceptable salts thereof. The present invention also relates to processes for preparing the same; a pharmaceutical composition and formulation containing a derivative of piperlongumine; and use of the derivatives and analogs for treating cancer.
    Type: Grant
    Filed: November 14, 2018
    Date of Patent: November 1, 2022
    Assignee: Auransa Inc.
    Inventors: Andrew Asher Protter, Michael John Green, Hak Jin Chang, Son Minh Pham, Sarvajit Chakravarty, Gregory R. Luedtke, Pek Yee Lum
  • 1,8-NAPHTHYRIDINONE COMPOUNDS AND USES THEREOF
    Publication number: 20220220111
    Abstract: 1,8-naphthyridinone compounds as modulators of an adenosine receptor are provided. The compounds may find use as therapeutic agents for the treatment of diseases mediated through a G-protein-coupled receptor signaling pathway and may find particular use in oncology.
    Type: Application
    Filed: December 13, 2021
    Publication date: July 14, 2022
    Inventors: Son Minh Phan, Jiyun Chen, Amantullah Ansari, Pradeep S. Jadhavar, Varshavekumar S. Patil, Farha Khan, Sreekanth A. Ramachandran, Anil Kumar Agarwal, Sarvajit Chakravarty
  • SUBSTITUTED 1,6-DIHYDROPYRIDINONES AND 1,2-DIHYDROISOQUINOLINONES AS BET INHIBITORS
    Publication number: 20220213122
    Abstract: Novel bromodomain and extraterminal domain (BET) inhibitors and to therapeutic methods of treating conditions and diseases using these novel BET inhibitors are provided.
    Type: Application
    Filed: December 2, 2021
    Publication date: July 7, 2022
    Inventors: Son Minh PHAM, Sarvajit Chakravarty, Jayakanth Kankanala, Jiyun Chen, Anjan Kumar Nayak, Anup Barde
  • Substituted pyrazolo[3,4-d]pyrimidines as Wee1 inhibitors
    Patent number: 11332473
    Abstract: This invention provides for substituted pyrazolo[3,4-d]pyrimidine compounds of the Formula (I): as Wee1 inhibitors. The substituted pyrazolo[3,4-d]pyrimidine compounds may find use as therapeutic agents for the treatment of diseases. The substituted pyrazolo[3,4-d]pyrimidine compounds may also find particular use in oncology.
    Type: Grant
    Filed: April 8, 2020
    Date of Patent: May 17, 2022
    Assignee: NUVATION BIO INC.
    Inventors: Sarvajit Chakravarty, Son Minh Pham, Jayakanth Kankanala, Brahmam Pujala, Sanjeev Soni, Puja Jaiswal, Deepak Palve, Varun Kumar
  • ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF
    Publication number: 20220135598
    Abstract: The present invention discloses compounds useful in treatment of conditions associated with dysfunction of ectonucleotide pyrophosphatase/phosphodiesterase-1 (ENPP1) enzyme. Specifically, the present invention discloses compound of formula (J) which exhibit inhibitory activity against ENPP1. Method of treating conditions associated with over-expression of ENPP1 gene with such compound is disclosed. Uses thereof, pharmaceutical composition, and kits are also disclosed.
    Type: Application
    Filed: November 1, 2021
    Publication date: May 5, 2022
    Inventors: Brahmam Pujala, Amantullah Ansari, Shreya Sapra, Pradeep S. Jadhavar, Dhananjay Pendharkar, Sreekanth A. Ramachandran, Uzma Saeed, Abhinandan Danodia, Farha Khan, Sagar Patni, Sanjeev Soni, Ashu Gupta, Sarvajit Chakravarty, Balaji Dashrath Sathe
  • Heterocyclic compounds and uses thereof
    Patent number: 11299493
    Abstract: Heterocyclic compounds as Wee1 inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.
    Type: Grant
    Filed: October 9, 2018
    Date of Patent: April 12, 2022
    Assignee: Nuvation Bio Inc.
    Inventors: Sarvajit Chakravarty, Son Minh Pham, Jayakanth Kankanala, Anil Kumar Agarwal, Brahmam Pujala, Sanjeev Soni, Satish K. Arya, Deepak Palve, Ashu Gupta, Varun Kumar
  • Diarylhydantoin compounds and methods of use thereof
    Patent number: 11292782
    Abstract: The disclosure relates to anti-cancer compounds derived from nuclear steroid receptor binders, to products containing the same, as well as to methods of their use and preparation.
    Type: Grant
    Filed: November 27, 2019
    Date of Patent: April 5, 2022
    Assignee: Nuvation Bio Inc.
    Inventors: Sarvajit Chakravarty, Son Minh Pham, Jiyun Chen, Jayakanth Kankanala, Jeremy D. Pettigrew, Anjan Kumar Nayak, Anup Barde, Brahmam Pujala
  • Inhibitors of integrated stress response pathway
    Patent number: 11230542
    Abstract: The present disclosure relates generally to therapeutic agents that may be useful as inhibitors of Integrated Stress Response (ISR) pathway.
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: January 25, 2022
    Assignee: PRAXIS BIOTECH LLC
    Inventors: Sebastian Bernales, Luz Marina Delgado Oyarzo, Gonzalo Esteban Núñez Vasquez, Gonzalo Andrés Ureta Díaz, Brahmam Pujala, Dayanand Panpatil, Bhawana Bhatt, Sarvajit Chakravarty
  • Compounds and Methods of Use
    Publication number: 20220000847
    Abstract: This disclosure provides compounds and compositions and methods of using those compounds and compositions to treat diseases and disorders associated with excessive transforming growth factor-beta (TGF?) activity. This disclosure also provides methods of using the compounds in combination with one or more cancer immunotherapies.
    Type: Application
    Filed: May 22, 2021
    Publication date: January 6, 2022
    Applicant: Medivation Technologies LLC
    Inventors: Roopa Rai, Sarvajit Chakravarty, Brahmam Pujala, Bharat Uttam Shinde, Anjan Kumar Nayak, Anil Kumar Agarwal, Sreekanth A. Ramachandran, Son Minh Pham
  • Substituted 1,6-dihydropyridinones and 1,2-dihydroisoquinolinones as bet inhibitors
    Patent number: 11192900
    Abstract: Novel bromodomain and extraterminal domain (BET) inhibitors contanining substituted 2-pyridones and therapeutic methods of treating conditions and diseases using these novel BET inhibitors are provided.
    Type: Grant
    Filed: October 30, 2019
    Date of Patent: December 7, 2021
    Assignee: Nuvation Bio Inc.
    Inventors: Son Minh Pham, Sarvajit Chakravarty, Jayakanth Kankanala, Jiyun Chen, Anjan Kumar Nayak, Anup Barde
  • Heterocyclic compounds as kinase inhibitors
    Patent number: 11174252
    Abstract: Heterocyclic compounds of Formula (J) as CDK4 or CDK6 or other CDK inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.
    Type: Grant
    Filed: February 15, 2019
    Date of Patent: November 16, 2021
    Assignee: NUVATION BIO INC.
    Inventors: Son Minh Pham, Sarvajit Chakravarty, Jayakanth Kankanala, Brahmam Pujala, Amit Shete, Bhawana Bhatt, Anil Kumar Agarwal, Sanjeev Soni, Jiyun Chen
  • Inhibitors of integrated stress response pathway
    Patent number: 11166942
    Abstract: The present disclosure relates generally to therapeutic agents that may be useful as inhibitors of Integrated Stress Response (ISR) pathway.
    Type: Grant
    Filed: June 5, 2019
    Date of Patent: November 9, 2021
    Assignee: PRAXIS BIOTECH LLC
    Inventors: Luz Marina Delgado Oyarzo, Gonzalo Andrés Ureta Díaz, Brahmam Pujala, Dayanand Panpatil, Sebastian Bernales, Sarvajit Chakravarty